The Herpesviridae are a large, diverse family of doublestranded DNA, enveloped viruses. There are eight human herpesviruses (HHVs): herpes simplex virus 1 (HSV-1) and HSV-2, Epstein-Barr virus (EBV), varicella zoster virus (VZV), human cytomegalovirus (HCMV), HHV-6 and HHV-7 (both of the genus Roseolovirus), and Kaposi's sarcoma-associated herpesvirus (KSHV) 1 . HHVs are ubiquitous in the human population and can establish latent infections that can be reactivated to cause various diseases. The prototypical herpesviruses HSV-1 and HSV-2 (the HSVs), which are members of the subfamily Alphaherpesvirinae (also known as the alphaherpesviruses), most commonly cause localized mucocutaneous lesions known as oral herpes lesions (HSV-1) or genital lesions (HSV-2) but can also cause meningitis and encephalitis. The other proto typical herpesvirus, EBV, a member of the subfamily Gammaherpesvirinae (also known as the gammaherpesviruses), is the most common cause of infectious mononucleosis and is causally associated with several malignancies, including Burkitt's lymphoma and Hodgkin's lymphoma.
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Although the pathogenesis of herpesviruses differs, they enter host cells through a similar mechanism and use a conserved set of viral glycoproteins for membrane fusion. Entry of herpesviruses into cells proceeds in two distinct steps (FIG. 1a) . First, the virus binds to the host cell through specific receptors, bringing the viral fusion apparatus in close proximity to the cell membrane. Some of these receptor-binding events trigger fusion, whereas others simply serve to tether the virus to the cell and are dispensable for fusion. Second, the viral membrane fuses with either the host plasma membrane or the endocytic vesicle membrane through the action of a viral fusion protein that perturbs the host membrane. Herpesviruses generally require more envelope proteins to accomplish entry than most other enveloped viruses, which often accomplish target cell binding and membrane fusion using a single viral envelope protein. Recent structural studies of herpesvirus envelope glycoproteins have shed light on the complex process of herpesvirus-host membrane binding and fusion. In this Review, we focus on the requirements for viral binding and fusion of the prototypical HHVs, HSV-1, HSV-2 and EBV, with a particular emphasis on the structural properties of the viral glycoproteins that are responsible for these functions. We include details of the conformational changes that may trigger fusion, and the functional domains that are present in the primary viral fusion protein and its regulators.
Cell tropism
HSVs have a broad cell tropism, as they infect a variety of host cells, including lymphocytes, epithelial cells, fibroblasts and neurons. The pathways of HSV entry are varied and depend on the host cell being targeted.
Although initial studies indicated that HSVs enter cells by direct fusion with the plasma membrane at neutral pH, further analyses revealed that HSV entry also can occur by endocytosis in either a pH-dependent or a pHindependent manner 2, 3 (FIG. 1b) . The route of entry differs between cell lines, and the reason why endocytosis is sometimes required is unclear. In fact, for some cells in which endocytosis is the required route of entry, cell surface expression of the viral glycoproteins that mediate entry causes cell-cell fusion 2 . None of the HSV entry glycoproteins require low pH to function, although low pH has been shown to result in minor conformational differences in envelope glycoprotein B (gB) 4, 5 . The ability to enter cells using multiple pathways may facilitate productive infection of the multiple cell types that are encountered by HSVs.
By contrast, EBV predominantly infects epithelial cells and B cells, but under some circumstances it can infect other cell types, such as monocytes 6 . The route of entry used by EBV is also cell type dependent: entry into epithelial cells occurs by direct fusion at the cell surface, whereas entry into B cells occurs via endocytosis in a pH-independent manner 7 .
Entry machinery
The herpesvirus envelope contains at least a dozen different glycoproteins, a subset of which mediates viral entry. The entry of herpesviruses is a complex process because it requires multiple glycoproteins and each of these glycoproteins is multifunctional (TABLE 1) ; each entry glycoprotein can bind multiple receptors, interact with other glycoproteins and/or undergo conformational changes to The virus binds to cellular receptors (purple or blue) via envelope glycoproteins (brown or yellow) to tether the virus to the host cell membrane. Some receptor-binding events serve simply to tether the virus to the cell (brown glycoproteins and purple receptors), whereas others trigger conformational changes in the entry glycoproteins that mediate membrane fusion (yellow glycoproteins and blue receptors). Following the fusion trigger, fusion of the viral and cellular membranes progresses through a hemifusion intermediate, in which the outer membrane leaflets mix. This is followed by full fusion, in which the inner membrane leaflets mix and a fusion pore is formed, resulting in the release of the viral capsid into the host cell. b | Routes of entry. Herpes simpex viruses (HSVs) and Epstein -Barr virus (EBV) can enter cells by fusion at the plasma membrane or fusion with an endocytic membrane after endocytosis.
Heterodimer
A compound consisting of two non-identical subunits (in this case, a dimer composed of one gH molecule and one gL molecule).
Proteoglycans
Proteins that contain an abundance of sugars, including one or more glycosaminoglycan chains, on their surface.
induce membrane fusion. Some glyco proteins are required for entry, whereas others simply enhance entry.
EBV and HSVs share three conserved glycoproteins that are required for fusion with all cell types: gB, gH and gL. gH and gL form a heterodimer, referred to as gH-gL. HSV fusion also requires the receptor-binding activity of gD, whereas EBV fusion with B cells (but not fusion with epithelial cells) requires the receptor-binding activity of glycoprotein 42 (gp42) . Glycoproteins that tether the virus to the cell but are not essential for entry include gC in HSVs, and gp350 (and its alternative isoform, gp220) and BMRF2 in EBV.
Tethering to cells
Both HSVs and EBV use glycoproteins to promote tethering to host cells. Viral entry can still occur in the absence of these glycoproteins, albeit at a lower efficiency, as tethering serves to concentrate the virus at the cell surface but does not specifically trigger fusion. HSVs tether themselves to host cells through the interactions of gB and gC with heparan sulphate on cell surface proteoglycans. Although gB is required for HSV fusion, its heparan sulphate-binding activity is not essential for this process 8 . By contrast, gC is not required for fusion of HSVs with host cells and is dispensable for viral attachment in vitro, although deletion of gC decreases the efficiency of virus binding to host cells 9, 10 . gB and gC also bind to the C-type lectin dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN; also known as CD209), facilitating attachment during infection of dendritic cells 11 . EBV tethers to B cells primarily through the interaction of gp350, one of the most abundant EBV envelope glycoproteins, with complement receptor type 2 (CR2; also known as CD21), a B cell-specific surface receptor [12] [13] [14] [15] [16] . Although gp350 is not strictly required for entry into B cells, its absence reduces infection efficiency 17 . gp350 is a single-pass membrane protein that, as a result of alternative splicing, is made in two forms with approximate masses of 350 kDa and 220 kDa. The aminoterminal residues (1-470) of both isoforms can bind CR2 (REF. 18 ), and no specific roles for either of the two forms have been determined. The structure of gp350 has been solved 19 , and the CR2-binding site maps to a glycan-free patch on the surface of the glycoprotein.
EBV tethering to CR2-expressing epithelial cells relies on gp350. In addition, EBV BMRF2, a transmembrane envelope glycoprotein with an integrin-binding RGD motif, can interact with β1 integrin and α5 integrin to mediate binding to oral epithelial cells that express these integrins 20, 21 .
Triggers of membrane fusion for EBV entry
Binding to the gp42 receptor on B cells. Tethering of EBV to host cells is not sufficient to trigger fusion; instead, EBV gp42 triggers fusion on binding human leukocyte antigen class II (HLA class II) on target B cells 22 . All three HLA class II isotypes -HLA-DR, HLA-DP and HLA-DQ -can bind gp42 and trigger fusion, although some HLA-DQ alleles are nonfunctional 23 . gp42 is a type II membrane protein that belongs to the C-type lectin superfamily; it contains an N-terminal transmembrane domain and a carboxy-terminal C-type lectin domain (CTLD). gp42 has sequence homologues in the closely related primate lymphocryptoviruses and 
Hydrophobic pocket
A groove or pocket in a protein that typically serves as a binding site and is composed of mostly hydrophobic amino acid residues.
functional homologues in other herpesviruses, such as gD from the HSVs (discussed later in this Review). gp42 is cleaved adjacent to the transmembrane domain in vivo to generate a functional soluble form of the protein 24 that can trigger viral fusion with B cells in the absence of membrane-bound gp42; a mutation of the gp42 cleavage site that blocks the production of soluble gp42 inhibits B cell fusion 25 . The structures of both HLA class II-bound and unbound gp42 have been determined 26, 27 (FIG. 2a,b) , and the structure of gp42 bound to HLA class II revealed three key structural features that relate well to mutagenic studies of gp42 . First, HLA class II binds to the gp42 CTLD (residues 94-221) at a site that is distinct from the canonical HLA-interactive site present in other CTLDs 27 , such as that of the mouse natural killer cell receptor LY49A, which forms complexes with major histocompatibility complex class I molecules, the mouse counterparts to HLA class I molecules. Only two amino acids of the β-chain of HLA class II make extensive contacts with gp42: glutamic acid 46 interacts with gp42 residue 220, and arginine 72 interacts with gp42 residues 104-107. Second, the N-terminal portion of gp42, which interacts with gH-gL via residues 36-81 (REF. 29 ), is flexible and not resolved in the structure. Last, residues within a hydrophobic pocket at the canonical ligand-binding site of gp42 are crucial for B cell entry 30 , indicating that this pocket may interact with another ligand during B cell entry. Crystallographic dimerization of HLA-bound gp42 via its N-terminal region has been observed 27 , although dimerization does not occur with high affinity in solution 31 ; hence, the oligomeric state of native gp42 at the viral envelope surface is not yet clear, but most biochemical studies to date suggest that it is monomeric.
Two regions of the protein displayed different conformations in the unbound and HLA class II-bound forms 26, 27 , possibly indicating a mechanism by which gp42 triggers membrane fusion upon receptor binding. First, the hydrophobic pocket of gp42 is widened in response to HLA class II binding, emphasizing the crucial and seemingly dynamic role of this pocket in EBV entry into B cells. It has been hypothesized that the gp42 hydrophobic pocket may contain a second, higheraffinity binding site for gH-gL, or a binding site for gB or for a cellular receptor 26 . Second, in the unbound structure, the flexible N-terminal region of the gp42 molecule (residues 87-93, between the gH-gL-binding region and the CTLD) contacts the HLA-binding site of another gp42 molecule. The N-terminal region also projects outwards from the CTLD in a path that is distinct from that observed in the HLA-bound structure. Changes in the gp42 N-terminal region could occur in response to receptor binding and could contribute to the triggering of fusion.
gp42 as a viral tropism switch. Whereas entry of EBV into B cells requires a complex of gp42, gH-gL and gB, entry into epithelial cells requires only gH-gL and gB. The addition of recombinant soluble gp42 can rescue the B cell infectivity of EBV lacking gp42 but inhibits membrane fusion with and entry into epithelial cells 32, 33 . This is likely to be the result of the soluble gp42 binding to gH-gL, as an N-terminal peptide of gp42 (spanning residues 36-81) that is sufficient for gH-gL binding also inhibits epithelial cell entry 29, 31 . Furthermore, this gp42 peptide inhibits EBV fusion with B cells when fusion is triggered in vitro by soluble gp42, although the peptide exhibits only minimal inhibition when gp42 and gH-gL are expressed in the same cell, probably owing to the formation of the gp42-gH-gL complex before exposure to inhibitory peptide at the cell surface.
Virions that are synthesized in B cells contain lower amounts of gp42 in their envelopes than virions synthesized in infected epithelial cells, owing to sequestration of gp42 by cellular HLA class II in the B cells; thus, virions released from B cells are more likely to infect epithelial cells 34 .
Hence, EBV appears to use gp42 as a switch of cell tropism. Interestingly, other herpesviruses, including the betaherpesviruses HCMV 35 and HHV-6 (REF. 36 ), also encode glycoproteins that redirect cell tropism by forming stable complexes with gH-gL. No such proteins forming stable complexes with HSV gH-gL have been reported.
Binding to the EBV gH-gL receptor on epithelial cells.
Entry into epithelial cells has only recently begun to be understood. The attachment of EBV to these cells requires only gH-gL, unlike binding to B cells [37] [38] [39] , and the binding of a soluble form of gH-gL to epithelial cells is reduced by small interfering RNA-mediated downregulation of αv integrins 40 . Integrins, which are broadly expressed receptors that mediate the attachment of cells to the surrounding tissue, seem to be intimately involved in EBV-epithelial cell attachment and fusion. Soluble gH-gL co-precipitates with αvβ6 integrin and αvβ8 integrin, but not with αvβ3 integrin, and the addition of soluble αvβ6 integrin or αvβ8 integrin induces fusion of cells expressing gH-gL and gB 40 . Taken together, these lines of evidence strongly suggest that EBV gH-gL binds these integrins and that this binding is sufficient to trigger EBV entry into epithelial cells.
Triggers of membrane fusion for HSV entry
Binding to gD receptors. The main HSV receptor-binding protein is gD. It binds three classes of receptors: herpesvirus entry mediator (HVEM), a member of the tumour necrosis factor receptor family; nectin 1 and nectin 2, which are cell adhesion molecules of the immunoglobulin superfamily; and 3-O-sulphated heparan sulphate [41] [42] [43] . Soluble forms of gD and its receptors can trigger fusion, indicating that the gD-receptor interaction does more than just tether the viruses to the cell [44] [45] [46] . It is not yet clear which receptors are important during in vivo infection, but in mouse models of both genital herpes and herpes simplex encephalitis, nectin 1 is the dominant receptor that is used by HSV-2 (REFS 47-49). Notably, nectin 1 is expressed in neurons, which are the site of HSV latency. Interestingly, the insertion of heterologous ligands into the gD sequence can be used to retarget HSV-1 to novel receptors, such as interleukin-13 receptor subunit α2 (IL-13Rα2) 50 and HER2 (also known as ERBB2) 51 . Nature Reviews | Microbiology (FIG. 2c) , and an N-terminal loop that contains all of the HVEM contact sites within gD, spanning residues 7-15 and 24-32 (REFS 52-54). gD residues 7-32 are required . gp42 binds HLA class II at a non-canonical site within the gp42 C-type lectin domain (CTLD) (yellow; residues 94-221). HLA-DR1 residues E46 and R72 (blue residues) make extensive contacts with gp42 residues T104, R105, E106, Y107 and R200 (green). The canonical CTLD interaction site lies on an opposite face of gp42 at a pocket lined with hydrophobic residues (magenta). Asterisks denote conformational changes in gp42 that are due to binding of HLA class II. When bound to HLA, gp42 loops at residue 158 (cyan) and 167 (red) are shifted and the hydrophobic pocket (HP) widens compared with their conformation in unbound gp42. Peptide loaded in the HLA class II molecule is coloured orange. b | Unbound EBV gp42 (PDB ID 3FD4). In the absence of HLA, the gp42 amino terminus projects outwards in a path that is distinct from that observed for HLA-bound gp42. The N terminus of gp42 is flexible, and the residues that bind to gH-gL (gp42 residues 36-81) were not resolved. c | Herpes simplex virus 1 (HSV-1) glycoprotein D (gD) bound to herpesvirus entry mediator (HVEM) (PDB ID 1JMA). A truncated form of the gD ectodomain (gD285) with high affinity for HVEM was crystallized in complex with HVEM. Asterisks denote the conformational differences that are seen in gD285 in the presence or absence of its receptor. In the presence of HVEM, the N terminus of gD285 (green) forms a loop that serves as the receptor-binding site and is stabilized by receptor binding. The carboxy-terminal region, residues 260-285, is disordered in the crystal. d | Unbound gD (PDB ID 2C3A). A cysteine was added to the C terminus of the gD ectodomain (gD 307C ), which stabilized a gD dimer. A monomer from this dimer is shown. The core of this gD forms an immunoglobulin fold (yellow) that is flanked by N-terminal (green) and C-terminal (red) extensions. In the absence of HVEM, the C-terminal region, which includes the pro-fusion domain, is anchored near the N-terminal region. The C terminus masks the receptor-binding site, and the N-terminal loop conformation is not present.
Heptad repeats
Structural motifs in the amino acid sequence of proteins, typically signalling the formation of a coiled coil, a structure that is common to viral fusion proteins.
Fusion peptides
Sequences of hydrophobic residues within a fusion protein; these sequences insert into a target cell membrane during the fusion event.
for fusion triggered by the binding of 3-O-sulphated heparan sulphate 55 . The binding of gD to nectin 1 and nectin 2 also involves residues at the gD N terminusmost notably, tyrosine 38 -as well as other residues within the core of gD 56, 57 . The C-terminal region of gD (encompassing residues 260-310) has been termed the 'pro-fusion domain' , as it is required to trigger fusion 44 . The structure of unliganded gD revealed that the N terminus is flexible in the absence of receptor, and the C terminus is anchored near the N terminus, masking the receptor-binding site 58 (FIG. 2d) . When the C terminus was locked in a 'receptorunliganded state' by introducing an intramolecular disulphide bond, receptor binding and virus entry were abrogated. This suggests that the C terminus of unbound gD autoinhibits the N-terminal receptor-binding site 58, 59 . Upon receptor binding, the C terminus moves, and this movement is necessary for the triggering of fusion 60 . Consistent with an autoinhibitory model, the deletion of portions of the gD C terminus increases the binding affinity of the protein for both nectin 1 and HVEM
.
Binding to the HSV gB receptors. gB can bind to paired immunoglobulin-like type 2 receptor-α (PILRα), an immune system regulator, to trigger viral fusion in the presence of gD 62 . The finding that gB binding to its receptor can trigger fusion is of particular interest, as it differs from the dominant model in which gD acts as the receptor-binding glycoprotein and gB acts strictly as a fusion protein. The in vivo significance of the gB-PILRα interaction has yet to be explored, but it mediates the infection of several cell lines in vitro 62, 63 , and it may play a minor part in HSV-2 entry into human retinal pigment epithelial cells 64 . In addition to PILRα, non-muscle myosin heavy chain IIA (NMMHCIIA; also known as myosin 9) 65 and myelin-associated glycoprotein (MAG) 66 (a protein expressed on neural tissues) have also been shown to interact with gB to trigger HSV-1 entry.
Binding to the HSV gH-gL receptor. Although the binding of gH-gL to its receptor has not been shown to be a crucial trigger for HSV entry, some studies have indicated a receptor-binding role for gH-gL. The gH of HSVs contains an RGD motif, which may mediate attachment to integrins but is not essential for virus entry 67 . A soluble form of gH-gL binds to αvβ3 integrin-expressing cells in an RGD motif-specific manner 68 , and the engagement of αvβ3 integrin by gH-gL in the virion may direct the route of entry of HSV-1 (REF. 69 ). In addition, soluble gH-gL binds cells independently of αvβ3 integrin and inhibits virus entry into a number of cell types in vitro 70 . Similarly, expression of HSV-1 (REF. 70 ) or HCMV 71 gH-gL in target cells inhibits infection, possibly by sequestering cellular receptors.
Conserved core fusion machinery
The HSV-1, HSV-2 and EBV receptor-binding activities described above trigger fusion but are not sufficient for the completion of fusion. Membrane fusion of HSVs and EBV with their host cells requires gB and gH-gL, which together form the core fusion machinery of herpes viruses. The structures of gB from HSV-1 and EBV demonstrate that it has structural homology to other viral fusion proteins and is probably a key fusion protein in herpesviruses 72, 73 . Viral fusion proteins can insert into target membranes and refold through large conformational changes to draw viral and target cell membranes together, resulting in the formation of a fusion pore. The role of gH-gL during viral fusion is less clear. Recently, the structures of the gH-gL complexes from HSV-2 and EBV, and a partial structure of pseudorabies virus gH, were solved [74] [75] [76] , helping to define their roles as regulators of fusion.
The role of gH-gL during membrane fusion. The specific role of gH-gL in fusion has been the most elusive among the roles of the required entry glycoproteins. Several studies previously suggested that gH-gL acts as a fusion protein, possibly mediating the hemifusion step 77 (FIG. 1a) . Moreover, peptides corresponding to the heptad repeats (common features of fusion proteins) of gH from HSV-1 were shown to inhibit fusion, and peptides corresponding to gH hydrophobic regions -candidate 'fusion peptides' -were shown to bind lipids [78] [79] [80] [81] [82] [83] . In addition, VZV gH-gL expressed alone using recombinant vaccinia virus was shown be sufficient for cell-cell fusion 84, 85 . Furthermore, gH-gL from HSV-1 was shown to promote fusion of the virion envelope with the outer nuclear membrane during viral egress 86 . Although these studies suggest that gH-gL has fusogenic capability, a more recent study was unable to demonstrate the ability of gH-gL to induce hemifusion 87 , and transfection of cells in a vaccinia virus-free setting demonstrated that a combination of VZV gH-gL and gB was required for fusion 66 . Most importantly, the recently solved crystal structures of the gH-gL ectodomains demonstrate that the gH-gL complex has no structural homology with any known fusion protein [74] [75] [76] and the candidate 'fusion peptides' of gH are buried 76 . Thus, the structural data support a model in which gH-gL acts not as a fusogen but primarily as a regulator of fusion through interactions with gB.
The gH-gL complex of HSV-2 has an unusual 'bootshaped' structure composed of three domains, with the N-terminal domain formed by both gH and gL 76 (FIG. 3a) .
The interface between gH and gL within this N-terminal domain is extensive, and the proteins probably require one another for proper folding. Interestingly, the structure of gH-gL from EBV has a more linear domain arrangement with considerably different interdomain packing arrangements and modified domain designations 74 (FIG. 3b) . This difference in the orientation of the N-terminal domains may represent static structural variation between the two protein complexes. Alternatively, the structural differences may reflect the fact that gH-gL domains can undergo dynamic rearrangement.
The domains of gH that are proximal to the viral membrane (EBV domains III and IV) are conserved among viruses and adopt similar arrangements in the HSV-2 and EBV structures. By contrast, the N-terminal domain of gH-gL has the most divergent sequence among the herpesviruses, suggesting that this Nature Reviews | Microbiology membrane-distal portion of the complex might interact with other virus-specific or cell-specific proteins. For example, the EBV gH domain II contains an integrinbinding KGD motif within an exposed loop. In addition, the EBV gH-gL domain arrangement creates a prominent interdomain groove, near the KGD motif and a domain I-II linker, that could serve as an interaction site for gp42 or an epithelial cell receptor. Using chimeric gL molecules composed of EBV and rhesus lymphocryptovirus sequences, a species-specific functional interaction between gH-gL and gB was mapped to EBV gL residues 54 and 94 (REF. 88 ). This gB interaction site on EBV gH-gL is distinct from that proposed for gH-gL from HSV-2. The gB interaction site of gH-gL from HSVs is proposed to lie further down the complex, just below the epitope for antibody LP11 (FIG. 3a) , on the surface of domain H2 in a region that is conserved between HSV-1 and HSV-2 (REF. 76 ).
Multiple regions of gH-gL are bound by neutralizing antibodies, possibly reflecting the fact that gH-gL must interact with several partners for function. For example, the neutralizing antibody LP11, which targets gH-gL from HSV-1, maps to the border of domains H1B and H2, whereas the neutralizing antibody 52S maps to the opposite face of the complex, in domain H2 (REF. 76) (FIG. 3a) . Similarly, the neutralizing antibody E1D1, which targets gH-gL from EBV, binds in domain I near residues 65 and 69, whereas the neutralizing antibody CL59 maps to domains III and IV 38, 39, 89 . Mutagenesis studies also indicate that both the membrane-distal and membrane-proximal domains of the gH-gL ectodomain promote fusion, consistent with gH-gL having multiple roles during entry. gH from HSVs is relatively tolerant of insertion mutations, although insertions in multiple domains reduce fusion efficiency and insertions at the membrane-proximal residues 791 and 799, downstream of the solved structure but before the transmembrane domain, abrogate fusion 67, 90 . Similarly, mutation of the membrane-proximal residue 594 in EBV gH abrogates epithelial and B cell fusion, whereas mutation of residue 595 enhances B cell fusion and decreases epithelial cell fusion 39 . At the other end of the complex, mutation of EBV gH residue 74, which lies in the domain I-II linker near the interdomain groove, moderately enhances fusion 89 . The structures of the gH-gL homologues depict only the ectodomains. However, mutagenesis studies indicate that the transmembrane domain and the cytoplasmic tail of gH also promote fusion [90] [91] [92] [93] . Although a soluble version of HSV gH-gL lacking the transmembrane domain and the cytoplasmic tail was shown to promote fusion 94 , fusion efficiency was greatly reduced.
gB: A conserved herpesvirus fusion protein.
The structures of the gB proteins from HSV-1 and EBV revealed surprising structural homology to both vesicular stomatitis virus glycoprotein G (VSV G), the sole fusion protein of VSV, and baculovirus gp64, the major envelope protein of baculoviruses that is necessary and sufficient for cell entry 72, 73, 95, 96 . This structural homology could not be predicted by sequence similarity and indicates The HSV-2 gH-gL heterodimer adopts a boot-like configuration, and its amino-terminal gH domain H1, comprising subdomains H1A and H1B, clamps gL and makes extensive contacts. The carboxy-terminal gH domains H2 and H3 are shown. Substitution mutations at gH residues 168 or 329 (magenta spheres) or insertion mutations at gH residues 300, 313, 316 or 317 (magenta sticks) prevent binding of the neutralizing monoclonal antibody (mAb) LP11. On the opposite face of the complex, substitution mutations at gH residues 536 or 537 (cyan spheres) prevent binding of the neutralizing mAb 52S. b | The ectodomain of the Epstein-Barr virus (EBV) gH-gL (PDB ID 3PHF). EBV gH-gL domain designations differ somewhat from those of HSV-2 gH-gL. Domain I comprises gL and the N terminus of gH. Domain II contains an eight-stranded β-sheet that forms a 'picket fence' separating domain I from a helical bundle within domain II that lies parallel to the fence. Domain III is mainly helical, and domain IV forms a β-sandwich. The EBV gH-gL heterodimer is more linear and elongated than the HSV-2 complex, because the interdomain packing arrangements of EBV gH-gL differ substantially from the arrangements of the HSV-2 complex. Packing angles differ by ~90° between domains I and II, and by ~45° between domains II and III. EBV gL residues Q54 and K94 (blue spheres) contribute to a functional interaction with EBV gB. A KGD motif (green sticks) is located in a prominent loop of domain II and lies adjacent to the helical linker between domains I and II. A mutation at residue L74 of gH (green spheres) near the linker results in increased promotion of fusion. Mutations at gH residues G594 or E595 (orange spheres) differentially affect fusion promotion. 
Epitope
The portion of an antigen (a protein that is capable of eliciting an immune response) which is recognized by a specific antibody directed against that antigen.
Fusion loops
Loops composed of hydrophobic residues that are present in class II and class III fusogens and perform the same function as the fusion peptides present in class I fusogens.
that, although gB does not promote herpesvirus fusion by itself, it has a similar fold to known fusion proteins and may undergo large conformational changes to bring about fusion. Evidence for gB refolding has yet to be obtained, but a model for 'pre-fusion gB' has been proposed 73 , and it seems likely that gB undergoes a refolding transition during fusion. Together, these proteins represent a newly defined class of fusogens, called class III, with structural characteristics that are distinct from the well-described class I fusogens, such as haemagglutinin from the influenza viruses, and class II fusogens, such as envelope (E) protein from the flaviviruses 97 . The gB proteins from HSVs and EBV are trimeric and contain five distinct domains (FIG. 4) . The fusion loops of gB are crucial for membrane fusion [98] [99] [100] ; they are located in domain I, which is close in the crystal structure to the expected location of the transmembrane region. The core of the protein is composed of an α-helical coiled coil, a feature that is typical of many viral fusion proteins, including those of class I and class III. Long linker regions leading into and out of domain I and domain II are hypothesized to permit a large-scale rotation that is necessary for the transition from pre-fusion to postfusion conformations. Mutational and antigenic analyses highlight the fact that multiple domains of gB and oligomerization are critical for gB function [101] [102] [103] . In the case of EBV, gB may participate in the determination of cell tropism 103 . Insertion mutations in all five of the gB domains can abrogate fusion, consistent with the concept that gB undergoes a complex and ordered refolding process to drive fusion 102, 103 (FIG. 4) .
Overall, the structures of gB from HSV-1 and from EBV are remarkably similar. The most noticeable difference between these structures is the position of domain IV, the crown domain that contains epitopes for neutralizing HSV-specific antibodies. The fusion loop sequences and electrostatic surfaces of the trimers also differ, perhaps indicating that they interact differently with phospholipids in the membrane of the host cell . Domain I contains hydrophobic fusion loops that insert into the target cell membrane. For crystallization, the hydrophobic residues in the EBV gB fusion loops were replaced with the corresponding residues from HSV-1 gB. The carboxy-terminal domain V packs against the coiled-coil core formed by domain III and proceeds through to domain I, headed towards the transmembrane (TM) region. This creates a hairpin-like organization of the structure such that the fusion loops and TM domain lie at the same end of the trimer. The locations of insertion mutations that reduce virus-host cell fusion without preventing gB expression are noted.
the gB structures more closely resemble the post-fusion VSV G structure. Furthermore, the gB fusion loops sit in close proximity to where the C-terminal transmembrane domain would lie, a feature that is shared with the structures of other fusion proteins in their post-fusion conformations, including the fusion proteins of influenza viruses and paramyxoviruses 97, 105 . However, nearly 50 residues at the C terminus of the gB ectodomain are absent from the structures of HSV and EBV gB proteins, and these residues could interrupt the perceived proximity between the fusion loops and the transmembrane domain. In addition, the epitopes for neutralizing gB-specific antibodies map to the surface of the solved structure of HSV-1 gB. Neutralizing antibodies are likely to recognize the pre-fusion structure of the protein, and at least some of these epitopes would probably be obscured in the post-fusion form of the protein. How gB undergoes the substantial folding changes to transition from the pre-fusion to the post-fusion conformations remains to be understood.
The gB cytoplasmic tail is not included in the crystal structures. However, many studies have highlighted its role in gB function; mutations in the HSV-1 and HSV-2 gB cytoplasmic tail can disrupt gB transport to the cell surface, reduce fusion or enhance fusion, depending on the location of the mutation 106, 107 . The cytoplasmic tail of HSV-1 gB expressed by itself can interact with membranes, possibly providing a mechanism for negative regulation of fusion 108 . Close but distinct regions within the EBV gB tail positively and negatively regulate fusion 109 . Furthermore, distinct mutations within the tail of EBV gB can cause increased levels of the protein at the cell surface and fusion that is independent of gH-gL 110 .
Collectively, these studies highlight the fact that, in addition to the structurally complex ectodomain of gB, several functional regions exist within the intracellular cytoplasmic tail of this protein.
Interaction of viral proteins
Triggering fusion of the viral envelope with the right host cells at the right time requires coordinated interactions among multiple entry glycoproteins (FIG. 5) . The best defined interactions are those of gp42 and gD with their receptors, as these interactions are stable enough for co-crystallization. EBV gp42 and gH-gL also interact with high affinity, and a structure of gH-gL bound to gp42 or the N-terminal peptide of gp42 should reveal how the complex forms. Details of the other glycoprotein interactions are not completely understood, as they are likely to be low-affinity and/or transient interactions and therefore difficult to capture using wild-type proteins. Upon binding their receptors, gD and gp42 must transmit a signal to gH-gL and/or gB. Several studies suggest that the interaction between gH-gL and gB is a critical step in membrane fusion, with gB being required for a committed and expanding fusion pore [111] [112] [113] [114] . EBV gp42 and gH-gL form a stable complex via the N terminus of gp42 (REFS 29, 115) . As gp42 inhibits epithelial cell entry 32, 33 , it is likely that the gp42-binding site on gH-gL overlaps with an epithelial receptor-binding site, possibly near the loop that contains an integrin-binding KGD motif (FIG. 3b) . Residues 54 and 94 in the gL protein of EBV contribute to a functional interaction with gB 88 , suggesting that the N-terminal region of gH-gL in EBV may physically interact with gB.
HSV gD has been reported to associate with both gH-gL and gB. Mutations in gD have revealed that the region of gD that interacts with gH-gL is in the profusion domain between residues 260 and 310, and the region that interacts with gB is located between residues 240-260 and also involves residues 304-305 (REF. 116 ). The interaction of gD with gH-gL and with gB has also been detected using bimolecular complementation. In this technique, proteins of interest are fused to inactive halves of a fluorescent protein and an interaction of the proteins is detected by restoration of fluorescence as the two halves are brought into proximity.
An association of HSV gH-gL with gB has been detected using bimolecular complementation, but it is unclear whether this interaction requires that gD first binds a receptor 111, 113 . It was proposed that the site on HSV gH-gL that interacts with gB overlaps with the epitope for the neutralizing antibody LP11, as this antibody inhibits the (gH-gL)-gB association 76 (FIG. 3a) . The (gH-gL)-gB interaction probably occurs before fusion rather than as a result of it, as some HSV gB-specific antibodies can block fusion without disrupting this association 117 . In addition, mutations within the gB fusion loops blocked this interaction as well as fusion, perhaps suggesting that gB must insert its fusion loops into the membrane before it interacts with gH-gL.
Whether the associations that were detected by bimolecular complementation represent functional interactions remains to be determined. Recently, it was suggested that the binding of gD to its receptor activates gH-gL and that this activated gH-gL subsequently triggers gB to drive fusion 94 . The interaction of gH-gL with gB does not appear to require coexpression of the proteins on the same membrane; in the case of the HSV and HCMV proteins, cell-cell fusion has been reported when gB and gH-gL were expressed on different cells 94, 118 .
Concluding remarks and key questions
Now that the gH-gL crystal structures have been obtained, the structures are known for all of the glycoproteins that are required for viral entry into the host cell (that is, gD, gB and gH-gL from HSV and gp42, gB and gH-gL from EBV) and for two of the cellular receptors that bind these viruses and trigger fusion (that is, HVEM and HLA class II molecules). These structures identify the most likely viral fusogen and illustrate conformational changes that may trigger fusion. Furthermore, these viral glycoproteins serve as targets for neutralizing antibodies, and each represents a potential target for antiviral therapy
. Inhibitors of entry that target either the viral glycoproteins or their receptors have been successful for HIV therapy 119 , and dissection of the EBV gH-gL-gp42 interactions has led to the identification of a high-affinity peptide inhibitor of EBV fusion 29, 115 . These herpesvirus protein structures can be used for rational design of novel attachment and/or fusion with a target cell at the plasma membrane or the endosomal membrane. Glycoprotein D (gD) forms a dimer, and regions near the carboxyl termini (red) occlude the receptor-binding site. After binding herpesvirus entry mediator (HVEM), the amino terminus of gD (green) forms a loop and displaces the gD C terminus that contains the pro-fusion domain (red). Nectin 1 (not shown) can bind to an overlapping site on gD and also displace the C terminus in a similar manner. The gB trimer also binds to a receptor and the gH-gL heterodimer may bind to a cellular receptor (grey). Different sites within the gD pro-fusion domain interact with gH-gL and gB, and gH-gL and gB may interact with each other in response to the binding of gD to its receptor. These interactions trigger gB to insert its fusion loops (orange) into the target membrane and to fold into its post-fusion conformation to mediate fusion of the viral and cellular membranes. b | Epstein-Barr virus (EBV) fusion with the B cell endosomal membrane. Glycoprotein 42 (gp42), a type II glycoprotein, is cleaved near its N terminus but is retained on the virion through the interaction between its N terminus and gH-gL. gp42 binds to human leukocyte antigen (HLA) class II molecules, causing a hydrophobic pocket (pink) on gp42 to widen. Conformational changes within gp42 and/or gH-gL trigger insertion of the fusion loops of gB into the membrane of the B cell. gB then refolds to a post-fusion conformation, thereby mediating membrane fusion. c | EBV fusion with the plasma membrane of an epithelial cell. Virus produced in B cells is deficient in gp42, and this deficiency can promote infection of epithelial cells by these viruses. gp42 can thus act as a tropism switch. In the absence of gp42, the gH-gL complex binds to a receptor such as integrin on the epithelial cell. After receptor binding, gH-gL interacts with gB and triggers insertion of the fusion loops into the cell membrane. gB then refolds to a post-fusion conformation, thereby driving membrane fusion.
Box 1 | Therapeutic benefits of structural studies
Currently, no inhibitors of herpesvirus entry are used clinically. However, studies of herpesvirus entry are valuable for the development of such inhibitors, which could take one of two forms: those that block interactions between a viral glycoprotein and either its cellular receptor or other viral glycoproteins, and those that prevent the fusion function of glycoprotein B (gB). For example, gp42 peptides that prevent viral fusion with B cells and epithelial cells have been identified. These peptides interfere with the interaction between the gH-gL complex and gp42 (an interaction that is required for infection of B cells) or an interaction between gH-gL and a receptor (an interaction that may be required for epithelial infection) 29 . High-throughput screening approaches using the biochemical assays that have been developed 115 may result in small-molecule inhibitors that interfere with normal gH-gL function during Epstein-Barr virus entry. The interactions between HSV gD, gB and gH-gL may also be exploited. Prevention of virus-host cell fusion has been successful in the case of HIV infections, as shown by the therapeutic success of enfuvirtide (Fuzeon; Roche), a drug that targets the HIV fusion protein. Many peptides have been designed that recognize heptad repeat regions in gB, and some of these peptides block fusion and entry, possibly by preventing the conformational changes that occur as gB refolds to its post-fusion form 122, 123 . Solving the gB pre-fusion structure would simplify the design of such inhibitors and improve our understanding of how they function. Furthermore, determining the structure of herpesvirus protein complexes and mapping the functional domains will allow a better understanding of why certain antibodies are neutralizing whereas others are not, and this may lead to the development of more effective vaccines to prevent herpesvirus infections.
EBV BMRF2 and of the tripartite gp42-gH-gL complex have not been solved. In addition, a structural comparison of the pre-fusion and post-fusion conformations of gB would shed light on how this protein refolds to mediate membrane fusion during virus entry. An analysis of the conformational changes that gB undergoes will provide a better understanding of the entry of other viruses that use class III fusogens, including VSV and baculoviruses. Although many viruses enter cells using a single protein for both attachment and fusion, herpesviruses are not alone in their complexity. Understanding how herpesvirus entry proteins interact may provide insight into the entry of paramyxoviruses, which use separate binding and fusion glycoproteins 105 , and poxviruses, which probably use even more entry proteins than herpesviruses 121 . inhibitors and to analyse inhibitors identified via drug screens. The ability to model the conserved glyco proteins gB and gH-gL from the other human and animal herpesviruses using these structures further expands their significance.
The structural examination of the proteins that mediate virus entry is ongoing, and current models of HSV and EBV fusion will continue to be refined (FIG. 5) . The structures of the receptors nectin 1, PILRα, MAG, NMMHCIIA, αvβ6 integrin and αvβ8 integrin remain to be solved, both alone and in complex with glycoproteins. Furthermore, it is likely that multiple entry receptors remain to be identified, as soluble forms of both HSV gB and HSV gH-gL bind to cells and inhibit virus entry 70, 120 . Of the viral proteins involved in entry, the structures of the tethering proteins HSV gC and
